Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P C F Oyston

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Medical Microbiology|October 30, 2010
Q fever: the neglected biothreat agentP C F Oyston, C Davies
Expert Opinion on Biological Therapy|July 2, 2003
A vaccine for tularaemiaR W Titball, P C F Oyston
Journal of Medical Microbiology|March 24, 2012
The natural history and incidence of Yersinia pestis and prospects for vaccinationE D Williamson, P C F Oyston
Clinical and Experimental Immunology|March 14, 2013
Protecting against plague: towards a next-generation vaccineE D Williamson, P C F Oyston
Clinical and Experimental Immunology|August 11, 2019
A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogensA Abraham, G Ostroff, S M Levitz, et al.
Journal of Medical Microbiology|June 17, 2009
Novel peptide therapeutics for treatment of infectionsP C F Oyston, M A Fox, S J Richards, et al.
Microbiology (Reading, England)|June 8, 2013
Synthetic biology: biology by designM A J Roberts, R M Cranenburgh, M P Stevens, et al.
Journal of Medical Microbiology|December 6, 2002
Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteinsS M Jones, J F Ellis, P Russell, et al.
Microbiology (Reading, England)|September 19, 2009
RelA regulates virulence and intracellular survival of Francisella novicidaR E Dean, P M Ireland, J E Jordan, et al.
Journal of Medical Microbiology|April 5, 2003
Expression of heterologous O-antigen in Yersinia pestis KIM does not affect virulence by the intravenous routeP C F Oyston, J L Prior, S Kiljunen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Medical Microbiology|October 30, 2010
Q fever: the neglected biothreat agentP C F Oyston, C Davies
Expert Opinion on Biological Therapy|July 2, 2003
A vaccine for tularaemiaR W Titball, P C F Oyston
Journal of Medical Microbiology|March 24, 2012
The natural history and incidence of Yersinia pestis and prospects for vaccinationE D Williamson, P C F Oyston
Clinical and Experimental Immunology|March 14, 2013
Protecting against plague: towards a next-generation vaccineE D Williamson, P C F Oyston
Clinical and Experimental Immunology|August 11, 2019
A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogensA Abraham, G Ostroff, S M Levitz, et al.
Journal of Medical Microbiology|June 17, 2009
Novel peptide therapeutics for treatment of infectionsP C F Oyston, M A Fox, S J Richards, et al.
Microbiology (Reading, England)|June 8, 2013
Synthetic biology: biology by designM A J Roberts, R M Cranenburgh, M P Stevens, et al.
Journal of Medical Microbiology|December 6, 2002
Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteinsS M Jones, J F Ellis, P Russell, et al.
Microbiology (Reading, England)|September 19, 2009
RelA regulates virulence and intracellular survival of Francisella novicidaR E Dean, P M Ireland, J E Jordan, et al.
Journal of Medical Microbiology|April 5, 2003
Expression of heterologous O-antigen in Yersinia pestis KIM does not affect virulence by the intravenous routeP C F Oyston, J L Prior, S Kiljunen, et al.
Pageof 2